PPT2-EGFL8

Across TCGA pan-cancer cohorts, PPT2-EGFL8 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PPT2-EGFL8’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PPT2-EGFL8 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PPT2-EGFL8 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

LIHC, COAD, and KIRC are the cancer types where PPT2-EGFL8 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PPT2-EGFL8 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.316	<.001	9	view →
COAD	Female	All	+0.257	<.001	9	view →
KIRC	Male	All	+0.139	<.001	7	view →
KICH	Female	All	−0.524	<.001	6	view →
CHOL	Male	All	+0.928	<.001	5	view →
LUSC	All	All	+0.180	<.001	5	view →
THCA	Female	II,III,IV	−0.231	.015	4	view →
BRCA	Female	All	−0.161	<.001	4	view →
LUAD	All	All	+0.128	.004	4	view →
READ	All	All	+0.197	.007	3	view →
BLCA	Female	IV	+0.413	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PPT2-EGFL8–LIHC

Open the LIHC breakdown →